See more : JVSPAC Acquisition Corp. Unit (JVSAU) Income Statement Analysis – Financial Results
Complete financial analysis of Mereo BioPharma Group plc (MREO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mereo BioPharma Group plc, a leading company in the Biotechnology industry within the Healthcare sector.
- AgriFORCE Growing Systems Ltd. (AGRIW) Income Statement Analysis – Financial Results
- Belships ASA (NS6.MU) Income Statement Analysis – Financial Results
- Qlife Holding AB (publ) (QLIFE.ST) Income Statement Analysis – Financial Results
- Sino-Thai Engineering and Construction Public Company Limited (STEC-R.BK) Income Statement Analysis – Financial Results
- Investeringsforeningen BankInvest – Børsnoterede Alternativer Akk. KL (BAIBAA.CO) Income Statement Analysis – Financial Results
Mereo BioPharma Group plc (MREO)
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00M | 1.51M | 36.46M | 393.00K | -122.00K | 0.00 | -3.29M | 0.00 |
| Cost of Revenue | 2.57M | 936.00K | 17.91M | 16.35M | 23.61M | 22.70M | 34.61M | 24.56M |
| Gross Profit | 7.43M | 571.00K | 18.56M | -15.95M | -23.73M | -22.70M | -37.89M | -24.56M |
| Gross Profit Ratio | 74.26% | 37.89% | 50.89% | -4,059.54% | 19,450.82% | 0.00% | 1,153.38% | 0.00% |
| Research & Development | 17.42M | 24.96M | 23.56M | -16.35M | -23.61M | 22.70M | 34.61M | 24.56M |
| General & Administrative | 18.42M | 19.54M | 15.93M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.42M | 19.54M | 15.93M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Other Expenses | 0.00 | 811.00K | 0.00 | 0.00 | 0.00 | 0.00 | -293.33K | 0.00 |
| Operating Expenses | 35.84M | 44.51M | 39.49M | 21.22M | 15.91M | 12.50M | 10.70M | 11.62M |
| Cost & Expenses | 38.42M | 43.57M | 57.40M | 37.57M | 39.52M | 35.21M | 45.30M | 36.18M |
| Interest Income | 2.13M | 696.00K | 1.00K | 44.00K | 377.00K | 306.83K | 826.86K | 195.14K |
| Interest Expense | 2.88M | 3.36M | 4.00M | 6.38M | 3.50M | 2.36M | 1.09M | 179.77K |
| Depreciation & Amortization | 1.06M | 1.51M | 866.47K | 44.00K | 1.95M | 37.80K | 36.08K | 32.94K |
| EBITDA | -26.06M | -42.06M | -5.00M | -37.53M | -37.56M | -34.86M | -44.44M | -38.41M |
| EBITDA Ratio | -260.56% | -2,791.11% | -55.71% | -9,548.35% | 30,789.34% | 0.00% | 1,352.72% | 0.00% |
| Operating Income | -28.42M | -43.57M | -20.94M | -37.57M | -39.52M | -35.21M | -45.30M | -36.18M |
| Operating Income Ratio | -284.16% | -2,891.11% | -57.42% | -9,559.54% | 32,390.98% | 0.00% | 1,378.99% | 0.00% |
| Total Other Income/Expenses | -1.58M | 7.48M | 40.16M | -129.27M | -1.60M | -2.10M | -1.65M | 2.46M |
| Income Before Tax | -30.00M | -36.09M | 14.24M | -166.45M | -41.12M | -37.31M | -46.95M | -33.72M |
| Income Before Tax Ratio | -299.98% | -2,395.02% | 39.05% | -42,353.69% | 33,703.28% | 0.00% | 1,429.13% | 0.00% |
| Income Tax Expense | -532.00K | -1.90M | 1.52M | -2.82M | -6.27M | -5.28M | -8.15M | -5.33M |
| Net Income | -29.47M | -34.20M | 12.73M | -163.63M | -34.84M | -32.03M | -38.80M | -28.39M |
| Net Income Ratio | -294.66% | -2,269.14% | 34.90% | -41,635.62% | 28,560.66% | 0.00% | 1,180.99% | 0.00% |
| EPS | -0.04 | -0.06 | 0.02 | -0.48 | -0.39 | -0.45 | -0.56 | -0.63 |
| EPS Diluted | -0.04 | -0.06 | 0.02 | -0.48 | -0.39 | -0.45 | -0.56 | -0.63 |
| Weighted Avg Shares Out | 659.45M | 603.20M | 527.82M | 337.72M | 89.34M | 71.14M | 69.01M | 44.79M |
| Weighted Avg Shares Out (Dil) | 659.45M | 603.20M | 555.28M | 338.95M | 89.42M | 71.14M | 69.01M | 44.79M |
Mereo BioPharma: An Overlooked Bio Company
Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares
7 Penny Stocks on a Tear Right Now and Still Worth Buying
Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital
Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020
Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports